The combination of phacoemulsification surgery and intravitreal triamcinolone injection in patients with cataract and diabetic macular edema

Özgür, Özlen Rodop; Özkurt, Yelda Buyru; Kulekci, Zeynep; Evciman, Tufan

doi:10.1016/j.sjopt.2015.10.004

Cited by 12 publications

(8 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was no factually huge contrast between the two gatherings in mean CMT preoperatively and second week, second month and third month after medical procedure . The mean CMT a half year after medical procedure was measurably altogether lower in bunch 1 than in bunch 2 [18].…”

Section: Phacoemulsification Combined With Intravitreal Triamcinolone Acetonide Injectionmentioning

confidence: 78%

See 1 more Smart Citation

Phacoemulsification Combined with Intravitreal Triamcinolone Acetonide Injection in Cataract Patients with Diabetic Macular Edema

Mohamed

Soliman

Mohamed

et al. 2020

Benha Journal of Applied Sciences

View full text Add to dashboard Cite

To assess the safety and efficiency of combined phacoemulsification surgery and intravitreal triamcinolone (IVTA) injection in patients with cataract and diabetic macular edema. This investigation included "40 patients" having youthful decrepit waterfall with clinically critical macular edema. Phacoemulsification was finished with back chamber intraocular focal point implantation and intravitreal triamcinolone infusion. Patients were followed up on day 1,day 3 then week after week for multi month, and from that point month to month for a half year postoperatively. Best adjusted visual keenness (BCVA) and focal macular thickness (CMT), and intraocular pressure (IOP) were recorded. All patients finished a half year of development. Mean BCVA demonstrated factually noteworthy improvement from a standard of 0.08 ± 0.05 decimal to 0.3 ± 0.13 decimal at 3 months and 0.35 ± 0.16 decimal at a half year . Mean CMT diminished essentially from a gauge of 504.85 ± 109.05 µm to 341.10 ± 75.35 µm at 3 months and 322.05 ± 87.40 µm at a half year. IOP was raised in 6 patients (15%) < 21 mmHg one month after infusion in any case, all managed with against glaucoma drugs. No infusion or medical procedure related difficulties were experienced. Phacoemulsification with simultaneous 4 mg IVTA infusion seems, by all accounts, to be a protected and compelling choice for overseeing diabetics with waterfall and CSMO.

show abstract

Section: Phacoemulsification Combined With Intravitreal Triamcinolone Acetonide Injectionmentioning

confidence: 78%

“…No infusion or medical procedure related intricacies were encountered [17]. [18] Examined 41 eyes of 36 diabetic patients with waterfall and coinciding clinically noteworthy macular odema (CSMO). After PHACO and IVTA infusion eyes were separated into two gatherings: the laser and IVTA gathering (Group 1) and just IVTA gathering (Group 2).…”

Section: Discussionmentioning

confidence: 99%

Phacoemulsification Combined with Intravitreal Triamcinolone Acetonide Injection in Cataract Patients with Diabetic Macular Edema

Mohamed

Soliman

Mohamed

et al. 2020

Benha Journal of Applied Sciences

View full text Add to dashboard Cite

show abstract

“…16 Ozgur and colleagues noted the efficacy of TA injections with CE as well as an advantage with the addition of laser at 6-month follow-up. 17 The IDI was chosen in our cases given its durability of effect in cases of recurrent ME secondary to RVO, DM, and noninfectious uveitis. In addition, the sustained-release pellet does not have the risk of clouding of vision associated with intravitreal TA.…”

Section: Discussionmentioning

confidence: 99%

“…16 Ozgur and colleagues noted the efficacy of TA injections with CE as well as an advantage with the addition of laser at 6-month follow-up. 17…”

Section: Discussionmentioning

confidence: 99%

Management of Pre-existing Macular Edema With Intravitreal Dexamethasone Implant in Eyes Undergoing Cataract Surgery

Smith

Banda

2019

Journal of VitreoRetinal Diseases

View full text Add to dashboard Cite

Purpose: The purpose of this study was to assess the efficacy and safety of intraocular dexamethasone implant (IDI) for pre-existing macular edema due to retinal vein occlusion (RVO), diabetes, and uveitis in eyes undergoing cataract surgery. Methods: A retrospective, noncomparative study was conducted. The medical record database was searched for patients meeting criteria of macular edema treated with IDI prior to cataract surgery. Results: Twenty-two patients had macular edema due to RVO (14 or 63.6%), diabetes (5 or 22.7%), or uveitis (3 or 13.6%). None had complications during cataract surgery. Thirteen (60%) were female with a mean age of 64 years (range, 25-82 years). The mean interval of dexamethasone implantation to cataract extraction was 49 days. The mean interval to follow-up optical coherence tomography was 65 days. Mean logarithm of the minimum angle of resolution (logMAR) visual acuity (VA) improved from .94 (20/150–) to .56 (20/70+) ( P = .004), with an average gain in VA measuring +0.37 logMAR (3 line gain). Mean central retinal thickness decreased from 474 to 378 μm ( P = .006) with an average reduction of 96 μm ( P = .006). Mean macular volume decreased from 10.29 mm3 to 9.78 mm3 ( P = .0002) with an average reduction of 0.51 mm3. Two patients developed postoperative ocular hypertension requiring treatment with topical antihypertensive agents. One had a combined glaucoma filtering procedure at the time of cataract surgery because of a history of ocular hypertension. Conclusions: The majority of this cohort had improved macular edema due to RVO, diabetes, and noninfectious uveitis while undergoing cataract surgery. IDI is an effective and safe treatment in these at-risk eyes.

show abstract

“…Lam et al, (2005), assessed the efficacy of phacoemulsification with 4 mg intravitreal triamcinolone injection in 19 eyes of 15 diabetic patients with cataract and diabetic macular edema with a follow-up of 6 months and found that 58.8% of eyes showed improvement in BCVA of >=2 lines (15) . Ozgur et al, (2016), Show that the BCVA during the 6 months of follow-up period after a successful PHACO surgery with 4 mg intravitreal triamcinolone injection was significantly higher than the initial BCVA (16), But Ahmadabadi et al, (2010), reported injection of triamcinolone after phacoemulsification had no effect on visual acuity (17). Anatomically, in this study, the central macular edema of patients who had phacoemulsification together with intravitreal triamcinolone injection showed reduction to a minimum CMT achieved at 6 th week and was sustained at 3 month.…”

Section: Discussionmentioning

confidence: 99%